



Lund November 19, 2014

EXINI enters collaboration with DexTech Medical

EXINI Diagnostics AB has signed a collaboration agreement with DexTech Medical AB as to a clinical phase-II study with the candidate drug OsteoDex. The agreement demonstrates the significance of BSI (Bone Scan Index) as a biomarker in the evaluation process of novel therapies for treating advanced prostate cancer with bone metastases.

The objective is to monitor the progression of bone-metastatic disease in castration-resistant prostate cancer patients, utilizing the software package EXINI bone^{BSI} in a clinical phase-II study of a new drug compound against bone metastases.

"We believe the technology developed by EXINI will enable more objective and valuable information to be extracted from the bone scan examinations planned", comments Anders Holmberg, CEO, DexTech Medical AB.

"Entering yet another collaboration around the use of BSI in clinical drug development is very positive for us", says Eva Bondesson, Medical Affairs Director, EXINI Diagnostics AB.

Read more:

www.exini.com

www.dextechmedical.com

www.bonescanindex.org

Or, please contact:

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market Nasdaq First North and has about 600 shareholders. Consensus acts as Certified Adviser.